Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate

Author: Benzinga Newsdesk | April 15, 2024 07:22am
Unity Biotechnology (NASDAQ:UBX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.77) by 63.64 percent. This is a 46.15 percent increase over losses of $(0.52) per share from the same period last year.

Posted In: UBX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist